KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives $29.17 Average Price Target from Brokerages

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) has been assigned an average rating of “Moderate Buy” from the nine ratings firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $29.1667.

Several analysts recently commented on the company. Citigroup reaffirmed a “market outperform” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, November 11th. Citizens Jmp cut their price target on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research note on Tuesday, November 11th. Wall Street Zen raised shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, October 8th. Finally, Cowen reaffirmed a “buy” rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd.

KalVista Pharmaceuticals Stock Down 2.4%

Shares of KalVista Pharmaceuticals stock opened at $14.60 on Friday. KalVista Pharmaceuticals has a twelve month low of $8.19 and a twelve month high of $19.00. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. The company’s 50 day moving average is $15.01 and its 200 day moving average is $13.74. The company has a market cap of $738.03 million, a price-to-earnings ratio of -3.70 and a beta of -0.14.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.04. The company had revenue of $13.69 million during the quarter, compared to the consensus estimate of $6.03 million. Research analysts anticipate that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

Insider Transactions at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, CEO Benjamin L. Palleiko sold 7,294 shares of the business’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $16.51, for a total transaction of $120,423.94. Following the completion of the sale, the chief executive officer owned 424,520 shares of the company’s stock, valued at approximately $7,008,825.20. The trade was a 1.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Paul K. Audhya sold 5,296 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $71,231.20. Following the completion of the transaction, the insider directly owned 131,831 shares in the company, valued at $1,773,126.95. This trade represents a 3.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 31,329 shares of company stock worth $437,371 in the last three months. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company lifted its position in shares of KalVista Pharmaceuticals by 5.9% in the second quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock valued at $165,000 after acquiring an additional 818 shares in the last quarter. BNP Paribas Financial Markets raised its stake in KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the period. Rhumbline Advisers lifted its holdings in KalVista Pharmaceuticals by 2.8% in the 2nd quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock worth $615,000 after purchasing an additional 1,458 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its holdings in KalVista Pharmaceuticals by 26.8% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,756 shares of the specialty pharmaceutical company’s stock worth $110,000 after purchasing an additional 2,061 shares in the last quarter. Finally, Profund Advisors LLC boosted its stake in KalVista Pharmaceuticals by 25.9% in the 3rd quarter. Profund Advisors LLC now owns 12,613 shares of the specialty pharmaceutical company’s stock worth $154,000 after purchasing an additional 2,593 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.